Francesca Romana Mauro | Ricerc@Sapienza

Francesca Romana Mauro

Professore Associato

Struttura:

DIPARTIMENTO DI MEDICINA TRASLAZIONALE E DI PRECISIONE

E-mail:

francescaromana.mauro@uniroma1.it

Pagina istituzionale corsi di laurea

Curriculum Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease	LEUKEMIA	2015
Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miR-132 and miR-212.	GENES, CHROMOSOMES & CANCER	2015
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments	LEUKEMIA RESEARCH	2015
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia	BLOOD	2015

Progetti di Ricerca

EFFICACY AND SAFETY OF DIRECT ORAL ANTICOAGULANTS (DOACS) OR OTHER ANTICOAGULANT/ANTIAGGREGANT TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED WITH IBRUTINIB: A MULTICENTER, REAL WORLD, OBSERVATIONAL STUDY.
CLINICAL AND SEROLOGICAL RESPONSE TO THE PNEUMOCOCCAL VACCINATION AFTER CHEMOIMMUNOTHERAPY OR ON KINASE INHIBITORS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL).
Severe infections and pneumonia in relapsed/ refractory (R/R) patients with chronic lymphocytic leukemia (CLL) treated in the real world with bendamustine and rituximab (BR) chemoimmunotherapy or the kinase inhibitors (KIs) ibrutinib or idelalisib.
BCR PATHWAY AND BCL-2 INHIBITORS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED IN THE CLINICAL PRACTICE: OUTCOMES AND REASONS FOR TREATMENT DISCONTINUATION. A REAL WORLD OBSERVATIONAL STUDY

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma